These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 29228726)

  • 1. Tyrosine kinase inhibitors show different anti-brain metastases efficacy in NSCLC: A direct comparative analysis of icotinib, gefitinib, and erlotinib in a nude mouse model.
    Tan J; Li M; Zhong W; Hu C; Gu Q; Xie Y
    Oncotarget; 2017 Nov; 8(58):98771-98781. PubMed ID: 29228726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations.
    He Q; Liu J; Cai X; He M; Li C; Liang H; Cheng B; Xia X; Guo M; Liang P; Zhong R; Li F; Yu Z; Zhao Y; Ou L; Xiong S; Li J; Zhang J; He J; Liang W
    Transl Lung Cancer Res; 2021 Nov; 10(11):4120-4129. PubMed ID: 35004243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Three Small Molecular Drugs for Targeted Therapy to Treat Nonsmall Cell Lung Cancer.
    Ni J; Zhang L
    Chin Med J (Engl); 2016 Feb; 129(3):332-40. PubMed ID: 26831237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of effectiveness and adverse effects of gefitinib, erlotinib and icotinib among patients with non-small cell lung cancer: A network meta-analysis.
    Liu Y; Zhang Y; Feng G; Niu Q; Xu S; Yan Y; Li S; Jing M
    Exp Ther Med; 2017 Nov; 14(5):4017-4032. PubMed ID: 29104622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An active treatment of lung adenocarcinoma cancer with brain metastases: icotinib.
    Zhang Y; Tang H; Li J; Li M
    Onco Targets Ther; 2015; 8():1351-4. PubMed ID: 26089684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer.
    Lee E; Keam B; Kim DW; Kim TM; Lee SH; Chung DH; Heo DS
    J Thorac Oncol; 2013 Aug; 8(8):1069-74. PubMed ID: 23804027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A real-world study in advanced non-small cell lung cancer with de novo brain metastasis.
    Lei L; Wang WX; Wang D; Lin L; Zhu YC; Wang H; Wang LP; Zhuang W; Fang MY; Wan B; Feng HJ; Xu CW
    J Cancer; 2021; 12(5):1467-1473. PubMed ID: 33531991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.
    Burotto M; Manasanch EE; Wilkerson J; Fojo T
    Oncologist; 2015 Apr; 20(4):400-10. PubMed ID: 25795635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Kashima J; Okuma Y; Miwa M; Hosomi Y
    Med Oncol; 2016 Nov; 33(11):129. PubMed ID: 27757781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies.
    Tan F; Shen X; Wang D; Xie G; Zhang X; Ding L; Hu Y; He W; Wang Y; Wang Y
    Lung Cancer; 2012 May; 76(2):177-82. PubMed ID: 22112293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.
    Shi Y; Zhang L; Liu X; Zhou C; Zhang L; Zhang S; Wang D; Li Q; Qin S; Hu C; Zhang Y; Chen J; Cheng Y; Feng J; Zhang H; Song Y; Wu YL; Xu N; Zhou J; Luo R; Bai C; Jin Y; Liu W; Wei Z; Tan F; Wang Y; Ding L; Dai H; Jiao S; Wang J; Liang L; Zhang W; Sun Y
    Lancet Oncol; 2013 Sep; 14(10):953-61. PubMed ID: 23948351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of icotinib and whole-brain radiotherapy in Chinese patients with brain metastases from non-small cell lung cancer.
    Fan Y; Huang Z; Fang L; Miao L; Gong L; Yu H; Yang H; Lei T; Mao W
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):517-23. PubMed ID: 26148750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequentially administrated of pemetrexed with icotinib/erlotinib in lung adenocarcinoma cell lines
    Feng X; Zhang Y; Li T; Li Y
    Oncotarget; 2017 Dec; 8(69):114292-114299. PubMed ID: 29371987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis.
    Chen Y; Wang M; Zhong W; Zhao J
    Lung Cancer; 2013 Nov; 82(2):313-8. PubMed ID: 24011632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR inhibitor-driven endoplasmic reticulum stress-mediated injury on intestinal epithelial cells.
    Hong S; Gu Y; Gao Z; Guo L; Guo W; Wu X; Shen Y; Sun Y; Wu X; Xu Q
    Life Sci; 2014 Dec; 119(1-2):28-33. PubMed ID: 25445223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy.
    Kim ST; Lee J; Kim JH; Won YW; Sun JM; Yun J; Park YH; Ahn JS; Park K; Ahn MJ
    Cancer; 2010 Jun; 116(12):3025-33. PubMed ID: 20564408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
    Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
    Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR.
    Hwang KE; Kwon SJ; Kim YS; Park DS; Kim BR; Yoon KH; Jeong ET; Kim HR
    Exp Cell Res; 2014 May; 323(2):288-96. PubMed ID: 24631288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.